Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Oktober 2022

Genmab — Oktober 2022

Planlagt Fastgjort Låst Flyttet Genmab
641 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • StockBullS Offline
    StockBullS Offline
    StockBull
    wrote on sidst redigeret af
    #627

    NBI +2.58%

    1 Reply Last reply
    0
    • K Offline
      K Offline
      kkjoel
      wrote on sidst redigeret af
      #628

      Her blir det moden Chateauneuf du Pape (2012 Pégau, Cuvée Laurence) til pandestegt Shawarmakød med hele baduljen: humus, Ajvar, grovpita, salat m/hvidløgsdressing og feta, oliven, den hotte strøg-chili(!) og turşu-chilier (tyrkiske sursyltede, milde grønne chilipebre). God weekend og Bon appetit 😉

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #629

        AbbVie Inc. (ABBV) Q3 2022 Earnings Call Transcript
        https://seekingalpha.com/article/4550412-abbvie-inc-abbv-q3-2022-earnings-call-transcript

        1 Reply Last reply
        0
        • Legolas23L Offline
          Legolas23L Offline
          Legolas23
          wrote on sidst redigeret af
          #630

          Ser man adds i us over hele handelsdagen laver den en Brontosaurus, der spiser palmeblade og kombineret med de største indeks luk i US forudser jeg en fin generel åbning. Jeg er forventningsfuld.

          1 Reply Last reply
          0
          • Legolas23L Offline
            Legolas23L Offline
            Legolas23
            wrote on sidst redigeret af
            #631

            Åbning mandag ?

            1 Reply Last reply
            0
            • B Offline
              B Offline
              bikube
              wrote on sidst redigeret af
              #632

              Ikke noget nyt fra AbbVie.

              1 Reply Last reply
              0
              • B Offline
                B Offline
                bikube
                wrote on sidst redigeret af
                #633

                Gmab endte i 2920 DKkr.

                1 Reply Last reply
                0
                • D Offline
                  D Offline
                  Doublo
                  wrote on sidst redigeret af
                  #634

                  Godformiddag kl. er 11.27 her i Tyrkiet mon vi opholder os på de samme breddegrader kkjoel? vi fik det lokale sprøjt, men til gengæld lammenyrer, solgte desværre en del i 2890 så ingen årgangsvine her.

                  1 Reply Last reply
                  0
                  • Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktør
                    wrote on sidst redigeret af
                    #635

                    I et bear-marked, hvor der raser recession på de økonomiske globale markeder, er det vigtig, man som investor har polstret sine porteføljer med aktier, som er både stresstestet og trykprøvet i deres evne til ikke at falde dybt ned, når der kommer negative nyheder. Og hvilke sektorer og aktier mener jeg, det er godt at være i? Det kan du høre om i denne video. https://www.proinvestor.com/boards/107378

                    1 Reply Last reply
                    0
                    • D Offline
                      D Offline
                      deleted-user
                      wrote on sidst redigeret af
                      #636

                      Highlight Abbvie Earnings Call "We're seeking accelerated approval based on the positive Phase 2 study results for epcoritamab in this indication where we saw very deep and durable responses in these highly refractory patients. We expect decisions in both U.S. and Europe in 2023."

                      1 Reply Last reply
                      0
                      • P Offline
                        P Offline
                        ProinvestorNEWS
                        wrote on sidst redigeret af
                        #637

                        Se ugens mange regnskaber: https://www.proinvestor.com/finanskalender

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #638

                          https://endpts.com/ema-limits-use-of-jak-inhibitors-for-at-risk-groups-in-wake-of-safety-concerns/

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #639

                            Ikke dårligt for RAPT Therapeutics da RPT193 gerne skulle ende op med en bedre safety profil

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #640

                              Hov det var den forkerte tråd

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #641

                                Y-mAbs Therapeutics with many former Genmab employees -49% atm on negative FDA decision on their neuroblastoma drug. (now trading at $4.50, were at $54 end2020...

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #642

                                  'While AbbVie does face several near-term pressures, we believe the firm is making strides with its pipeline, but probably needs to augment internal efforts with increased acquisitions. Within the pipeline, we are bullish on recently filed lymphoma drug epcoritamab.' https://www.morningstar.com/articles/1121828/abbvie-posts-solid-q3-earnings-but-uncertain-outlook-for-humira-likely-weighing-on-stock

                                  1 Reply Last reply
                                  0

                                  Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                  Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                  With your input, this post could be even better 💗

                                  Tilmeld Log ind
                                  Svar
                                  • Svar som emne
                                  Login for at svare
                                  • Ældste til nyeste
                                  • Nyeste til ældste
                                  • Most Votes


                                  • Log ind

                                  • Har du ikke en konto? Tilmeld

                                  • Login or register to search.
                                  Powered by NodeBB Contributors
                                  • First post
                                    Last post
                                  0
                                  • Kategorier
                                  • Seneste
                                  • Etiketter
                                  • Populære
                                  • Verden
                                  • Bruger
                                  • Grupper